alpn-303
alpine immune sciences
['alpn-303', 'alpineimmune']
today at #ash22, we are presenting data from alpn-303 s phase 1 study (ruby-1) in a poster presentation. stop by poster 3763 to learn more, or view the poster on our website: #alpnnews 
Modern therapies targeting the immune synapse. Founded 2015. (NASDAQ:ALPN)